GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. | GSK has continued ...

BioLife has improved its financials, with a dominant 70% market share in biopreservation media and high gross margins. Read why I'm neutral on BLFS stock.

Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic dysfunction-associated steatohepatitis to a market that could reach $16 billion by ...